Cargando…

Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial

INTRODUCTION: Oesophageal squamous cell carcinoma (OSCC) is one of the most commonly occurring devastating tumours worldwide, including in China. To date, the standard care of patients with stage IV OSCC is systemic chemotherapy and palliative care, which results in poor prognosis. However, no conse...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yun, Beeraka, Narasimha M, Liu, Junqi, Chen, Kuo, Song, Bo, Song, Zhang, Luo, Jianchao, Liu, Yang, Zheng, Anping, Cui, Yanhui, Wang, Yang, Jia, Zhenhe, Song, Xiangyu, Wang, Xiaohong, Wang, Hongqi, Qi, Xuefeng, Ren, Jinshan, Wu, Liping, Cai, Jixing, Fang, Xainying, Wang, Xin, Sinelnikov, Mikhail Y, Nikolenko, Vladimir N, Greeshma, M V, Fan, Ruitai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039379/
https://www.ncbi.nlm.nih.gov/pubmed/35470188
http://dx.doi.org/10.1136/bmjopen-2021-055273
_version_ 1784694115169992704
author Liu, Yun
Beeraka, Narasimha M
Liu, Junqi
Chen, Kuo
Song, Bo
Song, Zhang
Luo, Jianchao
Liu, Yang
Zheng, Anping
Cui, Yanhui
Wang, Yang
Jia, Zhenhe
Song, Xiangyu
Wang, Xiaohong
Wang, Hongqi
Qi, Xuefeng
Ren, Jinshan
Wu, Liping
Cai, Jixing
Fang, Xainying
Wang, Xin
Sinelnikov, Mikhail Y
Nikolenko, Vladimir N
Greeshma, M V
Fan, Ruitai
author_facet Liu, Yun
Beeraka, Narasimha M
Liu, Junqi
Chen, Kuo
Song, Bo
Song, Zhang
Luo, Jianchao
Liu, Yang
Zheng, Anping
Cui, Yanhui
Wang, Yang
Jia, Zhenhe
Song, Xiangyu
Wang, Xiaohong
Wang, Hongqi
Qi, Xuefeng
Ren, Jinshan
Wu, Liping
Cai, Jixing
Fang, Xainying
Wang, Xin
Sinelnikov, Mikhail Y
Nikolenko, Vladimir N
Greeshma, M V
Fan, Ruitai
author_sort Liu, Yun
collection PubMed
description INTRODUCTION: Oesophageal squamous cell carcinoma (OSCC) is one of the most commonly occurring devastating tumours worldwide, including in China. To date, the standard care of patients with stage IV OSCC is systemic chemotherapy and palliative care, which results in poor prognosis. However, no consensus has been established regarding the role of radiotherapy in targeting the primary tumour in patients with stage IVa OSCC. Thus, the aim of this study is to assess the effectiveness of primary radiotherapy combined with S-1 and nedaplatin (NPD) chemotherapy in the patients with stage IV OSCC. METHODS AND ANALYSIS: The study is a multicentre, open-label, randomised controlled trial. A total of 180 eligible patients with stage IV OSCC will be randomised into a study group (90 patients) and a control group (90 patients). Patients in the study group will receive radiotherapy to the primary tumour at a dose of 50.4 Gy combined with 4–6 cycles of S-1 and NPD chemotherapy. In the control group, patients will only receive 4–6 cycles of S-1 and NPD chemotherapy. The primary and secondary outcomes will be measured. The differences between the two groups will be statistically analysed with regard to overall survival, the progression-free survival and safety. All outcomes will be ascertained before treatment, after treatment and after the follow-up period. The results of this study will provide evidence on the role of radiotherapy in patients with stage IV OSCC in China, which will show new options for patients with advanced oesophageal cancer. ETHICS AND DISSEMINATION: This study was approved by the Institutional Ethics Committee of The First Hospital Affiliated of Zhengzhou University (approval number: SS-2018–04). TRIAL REGISTRATION: The trial has been registered at the Chinese Clinical Trial Registry (ChiCTR1800015765) on 1 November 2018; retrospectively registered, http://www.chictr.org.cn/index.aspx.
format Online
Article
Text
id pubmed-9039379
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-90393792022-05-06 Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial Liu, Yun Beeraka, Narasimha M Liu, Junqi Chen, Kuo Song, Bo Song, Zhang Luo, Jianchao Liu, Yang Zheng, Anping Cui, Yanhui Wang, Yang Jia, Zhenhe Song, Xiangyu Wang, Xiaohong Wang, Hongqi Qi, Xuefeng Ren, Jinshan Wu, Liping Cai, Jixing Fang, Xainying Wang, Xin Sinelnikov, Mikhail Y Nikolenko, Vladimir N Greeshma, M V Fan, Ruitai BMJ Open Oncology INTRODUCTION: Oesophageal squamous cell carcinoma (OSCC) is one of the most commonly occurring devastating tumours worldwide, including in China. To date, the standard care of patients with stage IV OSCC is systemic chemotherapy and palliative care, which results in poor prognosis. However, no consensus has been established regarding the role of radiotherapy in targeting the primary tumour in patients with stage IVa OSCC. Thus, the aim of this study is to assess the effectiveness of primary radiotherapy combined with S-1 and nedaplatin (NPD) chemotherapy in the patients with stage IV OSCC. METHODS AND ANALYSIS: The study is a multicentre, open-label, randomised controlled trial. A total of 180 eligible patients with stage IV OSCC will be randomised into a study group (90 patients) and a control group (90 patients). Patients in the study group will receive radiotherapy to the primary tumour at a dose of 50.4 Gy combined with 4–6 cycles of S-1 and NPD chemotherapy. In the control group, patients will only receive 4–6 cycles of S-1 and NPD chemotherapy. The primary and secondary outcomes will be measured. The differences between the two groups will be statistically analysed with regard to overall survival, the progression-free survival and safety. All outcomes will be ascertained before treatment, after treatment and after the follow-up period. The results of this study will provide evidence on the role of radiotherapy in patients with stage IV OSCC in China, which will show new options for patients with advanced oesophageal cancer. ETHICS AND DISSEMINATION: This study was approved by the Institutional Ethics Committee of The First Hospital Affiliated of Zhengzhou University (approval number: SS-2018–04). TRIAL REGISTRATION: The trial has been registered at the Chinese Clinical Trial Registry (ChiCTR1800015765) on 1 November 2018; retrospectively registered, http://www.chictr.org.cn/index.aspx. BMJ Publishing Group 2022-04-25 /pmc/articles/PMC9039379/ /pubmed/35470188 http://dx.doi.org/10.1136/bmjopen-2021-055273 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Oncology
Liu, Yun
Beeraka, Narasimha M
Liu, Junqi
Chen, Kuo
Song, Bo
Song, Zhang
Luo, Jianchao
Liu, Yang
Zheng, Anping
Cui, Yanhui
Wang, Yang
Jia, Zhenhe
Song, Xiangyu
Wang, Xiaohong
Wang, Hongqi
Qi, Xuefeng
Ren, Jinshan
Wu, Liping
Cai, Jixing
Fang, Xainying
Wang, Xin
Sinelnikov, Mikhail Y
Nikolenko, Vladimir N
Greeshma, M V
Fan, Ruitai
Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title_full Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title_fullStr Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title_full_unstemmed Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title_short Comparative clinical studies of primary chemoradiotherapy versus S-1 and nedaplatin chemotherapy against stage IVb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
title_sort comparative clinical studies of primary chemoradiotherapy versus s-1 and nedaplatin chemotherapy against stage ivb oesophageal squamous cell carcinoma: a multicentre open-label randomised controlled trial
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039379/
https://www.ncbi.nlm.nih.gov/pubmed/35470188
http://dx.doi.org/10.1136/bmjopen-2021-055273
work_keys_str_mv AT liuyun comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT beerakanarasimham comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT liujunqi comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT chenkuo comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT songbo comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT songzhang comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT luojianchao comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT liuyang comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT zhenganping comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT cuiyanhui comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT wangyang comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT jiazhenhe comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT songxiangyu comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT wangxiaohong comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT wanghongqi comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT qixuefeng comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT renjinshan comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT wuliping comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT caijixing comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT fangxainying comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT wangxin comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT sinelnikovmikhaily comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT nikolenkovladimirn comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT greeshmamv comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial
AT fanruitai comparativeclinicalstudiesofprimarychemoradiotherapyversuss1andnedaplatinchemotherapyagainststageivboesophagealsquamouscellcarcinomaamulticentreopenlabelrandomisedcontrolledtrial